181 related articles for article (PubMed ID: 35422628)
1. Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review.
Zhao Y; Cao Y; Wang X; Qian T
Onco Targets Ther; 2022; 15():345-351. PubMed ID: 35422628
[TBL] [Abstract][Full Text] [Related]
2. Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma.
Yang H; Ma Q; Sun Y; Zhang K; Xing Y; Li H
Front Oncol; 2022; 12():1065137. PubMed ID: 36620577
[TBL] [Abstract][Full Text] [Related]
3. Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review.
Zhang L; Wu Z
Clin Cosmet Investig Dermatol; 2023; 16():457-461. PubMed ID: 36846442
[TBL] [Abstract][Full Text] [Related]
4. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report.
Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J
J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597
[TBL] [Abstract][Full Text] [Related]
5. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review.
Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G
Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931
[TBL] [Abstract][Full Text] [Related]
6. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review.
Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N
Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673
[TBL] [Abstract][Full Text] [Related]
7. A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma.
Gong Y; Mao J; Liu M; Gao J
J Int Med Res; 2023 May; 51(5):3000605231173556. PubMed ID: 37211771
[TBL] [Abstract][Full Text] [Related]
8. Toxic Epidermal Necrolysis-like Reaction With Severe Satellite Cell Necrosis Associated With Nivolumab in a Patient With Ipilimumab Refractory Metastatic Melanoma.
Nayar N; Briscoe K; Fernandez Penas P
J Immunother; 2016 Apr; 39(3):149-52. PubMed ID: 26938948
[TBL] [Abstract][Full Text] [Related]
9. Toxic epidermal necrolysis associated with pembrolizumab.
Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A
J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421
[TBL] [Abstract][Full Text] [Related]
10. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report.
Li G; Gong S; Wang N; Yao X
Front Immunol; 2022; 13():989966. PubMed ID: 36090976
[TBL] [Abstract][Full Text] [Related]
11. Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report.
Lye YL; Shan B; Jia CH; Liu J; Hou J; Du WL; Feng R; Liang P
Ann Dermatol; 2023 May; 35(Suppl 1):S100-S102. PubMed ID: 37853877
[TBL] [Abstract][Full Text] [Related]
12. Epidermal programmed cell death-ligand 1 expression in TEN associated with nivolumab therapy.
Vivar KL; Deschaine M; Messina J; Divine JM; Rabionet A; Patel N; Harrington MA; Seminario-Vidal L
J Cutan Pathol; 2017 Apr; 44(4):381-384. PubMed ID: 28000240
[TBL] [Abstract][Full Text] [Related]
13. Adverse skin reactions induced by sintilimab in advanced lung squamous carcinoma: a case report and review of the literature.
Yan J; Ma N; Qiao WL; Liu KQ; Liu DW; Wang Y; Qiao TT; Hao XQ; Zheng MD
Ann Transl Med; 2022 Dec; 10(24):1411. PubMed ID: 36660611
[TBL] [Abstract][Full Text] [Related]
14. Sintilimab-Induced Autoimmune Diabetes in a Patient With the Anti-tumor Effect of Partial Regression.
Wen L; Zou X; Chen Y; Bai X; Liang T
Front Immunol; 2020; 11():2076. PubMed ID: 32973816
[TBL] [Abstract][Full Text] [Related]
15. [Drug-induced toxic epidermal necrolysis with secondary aspergillus fumigatus infection: a case report].
Zhang S; Liu XY; Zhang JZ; Cai L; Zhou C
Beijing Da Xue Xue Bao Yi Xue Ban; 2019 Oct; 51(5):977-980. PubMed ID: 31624410
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy (toripalimab and lenvatinib)-associated toxic epidermal necrolysis in a patient with metastatic liver cancer: A case report.
Huang KK; Han SS; He LY; Yang LL; Liang BY; Zhen QY; Zhu ZB; Zhang CY; Li HY; Lin Y
World J Clin Cases; 2022 Apr; 10(11):3478-3484. PubMed ID: 35611193
[TBL] [Abstract][Full Text] [Related]
17. Grover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.
Koelzer VH; Buser T; Willi N; Rothschild SI; Wicki A; Schiller P; Cathomas G; Zippelius A; Mertz KD
J Immunother Cancer; 2016; 4():47. PubMed ID: 27532022
[TBL] [Abstract][Full Text] [Related]
18. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review.
Logan IT; Zaman S; Hussein L; Perrett CM
J Immunother; 2020 Apr; 43(3):89-92. PubMed ID: 31651559
[TBL] [Abstract][Full Text] [Related]
19. Case Report: A Case Report and Literature Review on Severe Bullous Skin Reaction Induced by anti-PD-1 Immunotherapy in a Cervical Cancer Patient.
Li X; Qu LX; Ren YM; Hu C
Front Pharmacol; 2021; 12():707967. PubMed ID: 34504425
[No Abstract] [Full Text] [Related]
20. Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report.
Cao J; Li Q; Zhi X; Yang F; Zhu W; Zhou T; Hou X; Chen D
Transl Cancer Res; 2021 Aug; 10(8):3870-3876. PubMed ID: 35116686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
